MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/jc.2018-00957

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2019

Height as a Clinical Biomarker of Disease Burden in Adult Mitochondrial Disease.

Boal Rachel L, Ng Yi Shiau, Pickett Sarah J, Schaefer Andrew M, Feeney Catherine, Bright Alexandra, Taylor Robert W, Turnbull Doug M, Gorman Grainne S, Cheetham Tim, McFarland Robert

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

CONTEXT: Abnormal growth and short stature are observed in patients with mitochondrial disease, but it is unclear whether there is a relationship between final adult height and disease severity.

OBJECTIVE

To determine whether patients with genetically confirmed mitochondrial disease are shorter than their peers and whether stature is related to disease severity.

DESIGN

Analysis of final adult height in relation to disease severity as determined by the Newcastle Mitochondrial Disease Adult Scale (NMDAS).

SETTING

UK Mitochondrial Disease Patient Cohort (Mito Cohort).

PATIENTS: 575 patients were identified with recorded height, weight, and molecular genetic diagnosis of mitochondrial disease within the Mito Cohort.

MAIN OUTCOME MEASURES: Adult height, body mass index (BMI), and their association with genetic subgroup and disease severity.

RESULTS

Adults with mitochondrial disease were short, with a mean height of -0.49 SD (95% CI, -0.58 to -0.39; n = 575) compared with UK reference data. Patients were overweight, with a BMI SD of 0.52 (95% CI, 0.37 to 0.67; n = 472). The most common genetic subgroup (m.3243A>G mutation) had a height SD of -0.70 (95% CI, -0.85 to -0.54; n = 234) and a BMI SD of 0.12 (95% CI, -0.10 to 0.34; n = 212). NMDAS scores were negatively correlated with height SD (r = -0.25; 95% CI, -0.33 to -0.17; P < 0.001, n = 533). Rate of disease progression also correlated negatively with adult height (P < 0.001).

CONCLUSION

Final height in mitochondrial disease reflects disease severity and rate of disease progression. Mitochondrial dysfunction and associated subclinical comorbidities affect growth plate physiology.

Для цитирования: Boal Rachel L, Ng Yi Shiau, Pickett Sarah J, Schaefer Andrew M, Feeney Catherine, Bright Alexandra, Taylor Robert W, Turnbull Doug M, Gorman Grainne S, Cheetham Tim, McFarland Robert. Height as a Clinical Biomarker of Disease Burden in Adult Mitochondrial Disease.. The Journal of clinical endocrinology and metabolism. 2019. DOI: 10.1210/jc.2018-00957.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.